The following background information on HCV in China is abstracted from Gideon www.GideonOnline.com and the Gideon e-book series. [1,2] Primary references are available on request.
PREVALENCE SURVEYS (ANTIBODY AND / OR VIRAL RNA):
GENERAL POPULATION:
Hepatitis C accounts for 8% of acute hepatitis Cases in Nanchong (2004 publication) to 18.1% of acute hepatitis in the Beijing area (1995 to 2000)
4.07% of the general population in 1997; 3.0% in 1999 (estimates)
0.58% nationwide (six regions, 2009 publication)
0.15% of adults in Liangshan Prefecture, Sichuan Province (2011 publication)
8.2% of rural adults in Shanxi – 27.7% of former commercial blood / plasma donors (2003)
0.9% of persons in Anyang (2006 to 2008)
0.5% of normal subjects (and 5.0% of liver disease patients) in Nanjing (1997 publication)
31.0% of persons in central Tibet (2001)
1.1% to 2.7% of the general population of Beijing
9.6% of elderly adults in Linxian (rural Henan) (2000)
BLOOD DONORS:
8.68% of blood donors – 12.87% prior to 1998 (15.78% during 1994 to 1995) , and 1.71% after 1998 (analysis of 265 studies, 2011 publication)
0% to 1.1% of volunteer blood donors (1997)
29.19% of non-remunerated blood donors in Shaoxing (2007 publication)
30% of professional blood donors in Hebei and Inner Mongolia
1.5% to 3% in professional blood donors from Liaoning and Anhui (1993 publication)
0.49% of blood donors in Chongqing (2008 publication)
0.53% of blood donors in Chengdu (2006 to 2007)
0.335% of voluntary blood donors in Guangzhou (2004 to 2007)
12.7% of former commercial blood / plasma donors in rural Shanxi Province (2004)
INJECTING DRUG USERS (IDU): As of 2011, an estimated 10 million injecting drug users worldwide are seropositive toward Hepatitis C virus – including 1.6 million in China.
32.35% of IDU (15 cities, 2011 publication)
4.0% of IDU (2010 publication)
66.97% of IDU (range 11.43% in Shaanxi to 90.77% in Hubei) vs. 18.37% of non-injecting drug users (literature review, 2009)
61.4% of IDU in China, with highest rates in Hubei, Yunnan, Guangxi, Hunan and Xinjiang (2008 publication)
71.0% of IDU in Sichuan (2002); 67.49% in Guangzhou
69.7% of IDU in Wuhan (2006 publication)
63.2% of IDU in Dongguan, Guangdong (2008)
71.6% of IDU in Guangdong (2010 publication)
94.3% of IDU on methadone maintenance, in Wuhan (2008 publication)
69.0% of Chinese and 48.1% of Burmese IDU in the China-Burma border region (2011 publication)
56.9% of HIV-positive IDU (2003 publication)
HIV-POSITIVE PATIENTS:
78.6% of HIV-positive former blood donors (Hubei, 2008 publication)
76.4% of HIV-positive patients vs. 2.5% of HIV-negative individuals (Shanxi Province, 2010 publication)
41.83% of HIV-positive patients (2007 to 2008)
59.0% of HIV-positive patients (Shanxi, Zhejiang, Yunnan and Xinjiang, 2011 publication)
9.6% of HIV-positive children receiving ART (2009 publication)
19.4% of HIV-positive patients receiving AART (Beijing, 2005 to 2007)
83.6% of AIDS patients were found to be co-infected with hepatitis C, 2.3% singly co infected with hepatitis B, and 5.5% co infected with HIV/HCV/HBV; 8.6% were infected with HIV only. (Zhengzhou, publication 2006)
MEN WHO HAVE SEX WITH MEN (MSM)
0.4% of MSM in 2004; 5.2% in 2006 (Beijing)
0.8% of MSM in Beijing (2005 to 2006)
0.4% of MSM in Beijing (2008 publication)
0.7% of MSM in Jiangsu (2006 to 2007)
0% of MSM in Taizhou city, Zhejiang province (2008 publication)
COMMERCIAL SEX WORKERS (CSW) / CLIENTS:
6.8% of CSW in Kunming, Yunnan (2008 publication)
8.7% of male clients of CSW in Sichuan (2010 publication)
PATIENTS WITH HEPATITIS / LIVER DISEASE:
14% to 27% of patients with chronic hepatitis
16% of hepatitis B carriers
43% of patients with cirrhosis
39% of patients with hepatocellular carcinoma
HEMODIALYSIS PATIENTS:
54% of hemodialysis patients and 6% of commercial blood donors – rates somewhat higher among carriers of Hepatitis GB-C. (Beijing, 1996)
41% of hemodialysis patients (meta-analysis, 2009 publication)
17.2% of hemodialysis patients in Zhejiang (2009 publication)
OTHER:
1.72% of patients with oral lichen planus (2010 publication)
1.30% of subjects with thyroid autoantibodies vs. 0.53% of a control group (2011 publication)
Primary liver cancer, one of the principal sequelae of Hepatitis C, is the second most common malignancy in China, responsible for 360,000 incident cases, and 350,000 deaths per year. Mortality rates of liver cancer were 17.6 and 7.3 per 100,000 for males and females during 1973 to 1975, 29.0 and 11.2 per 100,000 during 1990 to 1992, and 37.55 and 14.45 per 100,000 during 2004 to 2005.
References:
1. Berger SA. Infectious Diseases of China, 2011. 635 pp, 253 graphs, 3049 references. Gideon e-books, http://www.gideononline.com/ebooks/country/infectious-diseases-of-china/
2. Berger SA. Hepatitis C: Global Status, 2011. 164 pp, 160 graphs, 1500 references. Gideon e-books, http://www.gideononline.com/ebooks/disease/hepatitis-c-global-status/
Note featured on ProMED